|
| |
| Agenda |
|
|
|
|
PROGRAM AGENDA:
DAY 1 (Friday 25th April 2010) |
| 08:30 – 09:15 AM : Registration & Refreshments |
| General Session : Moderator : S. Krishnakumar : Head – Corporate Business Devlopment, Warnbury Ltd |
| 09:15-09:25 |
Opening Address – Satya Brahma, Editor-In-Chief, Pharma Leaders.
Release of an exclusive white paper on Booming Pharma Industry – The Road Ahead 2015. |
| 09:25-09:55 |
Welcome Address : Ajit Singh, Chairman, ACG Worldwide
Inaugural Address : Tapan Ray, Director General, OPPI. |
| 09:55 – 10.25 |
Address By Shri Ashok Chavan, Hon’ble Chief Minister, Government of Maharastra. |
| 10.25 – 10.55 |
Address by Shri Srikant Jena, Hon’ble Union Minister of State for Chemicals & Fertilizers, Government of India. |
| 10.55 – 11.25 |
Address by Shri Sanjay Nirupam, Hon’ble Member of Parliament, Government of India. |
|
11.25 – 11.55 |
Keynote Address: Dr Surinder Singh,DCGI,Ministry of Health & Family Affairs |
| 11.55 – 12.25 |
Keynote Address: Ranjit Shahani - President,OPPI,Vice-Chairman & MD, Novartis India Ltd. |
| 12.25 – 12.55 |
Keynote Address : Habil F Khorakiwala, Chairman, Wockhardt Ltd. |
| 12.55-01.25 |
Keynote Address: Leadership in the Face of Change...Mastering Resiliency : The Road Ahead.
Kewal Handa : Managing Director – Pfizer Ltd |
| 01.25 -02.25 |
Networking & Luncheon at Majestic Hall |
| 02.25 – 02.55 |
Keynote: Preventive Personalised Healthcare - The way Forward"
Dr.Villoo Morawala-Patell, Founder and CMD, Avastagen Ltd.
Most Indian biotech companies survive by doing reverse engineering or contract work but Morawala-Patell set out to give Avesthagen a strong focus in innovative R&D in diverse areas such as bioAgriculture, bioNutrition, biopharmaceuticals and drug discovery. And now she has split these four strategic business units as four independent profit and loss (P&L) entities, so that it can take care of its own financial requirements. With a fifth of small European biopharmaceutical companies possibly facing bankruptcy by the end of the year, the fear is that many Indian biotech companies could also face the same fate, thanks to the liquidity and credit crisis. The presentation will dwell on about the ripple effect on the Indian biotech |
| 02.55 – 03.25 |
Is the era of Blockbuster Molecule over??
Anuj Saxena, Managing Director, Elder Healthcare Ltd.
The days of the $1 billion blockbuster drug are over, according to a senior industry researcher. Big pharma is now investing in finding multiple uses for medicines developed to treat rare diseases, but is pushing the EU for regulatory changes to make research worthwhile. A 'blockbuster' drug is usually defined as a single medicine that treats one disease and generates revenue of more than $1 billion per year (€664 million). Bestselling medicines like the cholesterol-busting drug Lipitor can clock up sales of almost €8 million a year, although it comes off patent in a couple of years' time. Nevertheless, there has been much angst in the pharmaceutical sector in recent years as the pipeline of new groundbreaking medicines for common illnesses appears to be drying up. This comes at a time when advances in gene therapy and personalised medicine suggest the days of finding a mass-market drug to sell to large volumes of patients may be coming to an end. Pharmaceutical firms have been criticised in the past for their quest to find the next blockbuster for chronic conditions affecting patients in the developed world. This, say critics, has come at the expense of people with rare diseases, because it has not always been viewed as economically worthwhile to research uncommon illnesses or those affecting poorer populations |
| 03:25-03:55 |
Bulk Drug & API’s : Challenges & Opportunities Ahead!!!
Dr.B.P. S Reddy, Chairman Hetro Drugs Ltd
The Active Pharmaceutical Ingredient (API) industry in India is gearing up to grab the fast growing global market opportunities through quality manufacturing and R&D activities even as global pharma majors are looking towards low cost quality manufacturing centres in the emerging nations.According to the latest figures from the Bulk Drug Manufacturers Association (BDMA), the size of the API industry is about Rs 32000 crore to Rs 35000 crore ($6.61 billion to $7.23 billion) of the total Rs 78000 crore ($16.12 billion) Indian pharma industry. Out of the total API business, almost Rs 15000 crore to Rs 18000 crore ($3.1 billion to $3.7 billion) comes from exports. While the increase in volume-wise production for the domestic pharma industry has resulted in a growth of domestic market for APIs, the increasing number of companies exploring overseas market and the growth of generic potential in the most regulated and rich markets like the US and Europe has created a huge opportunity for Indian companies in exports business. The aggressive market exploration of Indian companies in overseas countries, especially in the semi-regulated and regulated markets are a major reason for the fast growth of the API industry. According to a study conducted by Ernst and Young for the Indian Brand Equity Foundation (IBEF), published in December 2008, the semi regulated markets account for a majority of bulk drugs exports with a 60 per cent share.However, the major Indian companies which are pursuing the regulated market as a large number of products have started losing their patent protection in these countries in last two years, are aggressively filing drug master files (DMFs) with the drug regulators in the US and Europe. |
| 03:55-04.25 |
Authorised Generics: Threat or Opportunity?
Mr.Satish Reddy, Managing Director, Dr Reddy’s Labs Ltd.
Over the last few years, a growing number of ‘authorised generic’ agreements have been evident in the US and most branded companies have issued them in order to take sales and profits away from 'hostile' generic competition. While there is currently nothing to stop a branded company from issuing a licensed generic during the period of 180 days exclusivity, it has been argued that authorised generics are counter to the spirit of Hatch-Waxman, and devalue the 180-day exclusivity period by destroying the incentive for generic companies to challenge patents. Certainly some Indian companies such as Ranbaxy and Dr. Reddy’s have been quick to exploit this opportunity, and the new products coming up, combined with their experience, will make them well placed to develop this area further. |
| 04.25-05.00 PM |
Break – Refreshments |
| 05.00 – 05.30 |
Competitive Intelligence and the Law: Myths and Facts
This presentation will explain the legal basis of Competitive Intelligence. Learn that collecting competitive information on a competitor is not only legal but also encouraged by the law. In addition learn how to understand what makes an information collection technique illegal and and how to recognize the line between law and ethics. Specific topics to be discussed include what is a “gray zone,” and whether it is legal to overhear a competitor on an airplane, to pick up a competitor’s lost document in the street, or to misidentify oneself as a student. The presentation also explains why abiding by the ethical standard will spare CI professionals and their companies potential legal problems and will explain why the Economic Espionage Act does not affect CI activities that are practiced in an ethical manner.
Ram Jethmalini, Former Minister of Law, Govt of India & Noted Lawer. |
| 05:30-06:00 |
How to build a robust financial global pharma empire?
Pravin Iyer, CEO, Medreich Ltd
Competition, typically the most powerful external force, is increased by the advent of globalization. The number of companies and the number of countries where these companies operate and the way governments are dealing with the impacts of globalization is accelerating. The interaction of changes in government policy and business innovation has actually made globalization even faster. If a company does not become a global, it would simply be shut out of new markets. The reasons for the turmoil are numerous: a sputtering economy, increased global competition, the implementation of new technologies that displace jobs, the deregulation of certain industries, and the general consolidation of other industries, such as banking and health care. Observers will see a continuing progression in the ruinous steps which have forced the industry into a socio-politico-economic corner. The industry is likewise linked closely to the policies of governments, the earnings of banks. The industry’s approach to dealing with political institutions has not always been brilliant. It tends to be good on technical issues, although it has not always fully presented the longer-term options, in order to make the choices and their implications clear. A competitive and complex make-up would thoroughly describe the structure of the pharmaceutical industry of today. Many companies are coming out of nowhere and are competing with some of the world’s oldest and most trusted pharmaceutical companies. The demand for high quality medicine never lessens. And so, competition is always an item. Industries strive hard to make medicine which is much more effective and cost-efficient than the rest. But how can one address and meet the demands of people? With the use of marketing strategies. A marketing strategy, as we can clearly understand, is a way of using all the resources you have in order to gain a better marketing opportunity. Though, a person may have limited financial, or whatever resources that he has limited supply of, he can still be able to pull off a great advantage in the marketing world through good marketing strategy. A great marketing strategy is the foundation of a great marketing plan. And just what is a marketing plan? It is an overall plan on how the producer is going to tackle the different components of selling his product. A marketing plan often entails the help of a great marketing strategy. For example, "Use a low cost product to attract consumers. Once our organization, via our low cost product, has established a relationship with consumers, our organization will sell additional, higher-margin products and services that enhance the consumer's interaction with the low-cost product or service." |
| 06:00-06:30 |
Networking & Refreshments in Exhibition Hall |
|
06:30-07:00 |
Venket Jasti, MD, Suven Life Sciences Ltd.
Obama’s Healthcare Policy & Its effects on India. |
| 07.00 –07.30 |
P.K.Guha, Jt MD, Zuventus Healthcare Ltd
How to avert a Brand Flop & the Art of Making a Blockbuster Molecule |
| 07:30-08:00 |
Tea & Cofee Break |
| 08.00 –08.30 |
Shailesh Iyenger, MD, Aventis Pharma Ltd.
How Pharma Leaders Can Survive and Thrive In Turbulent Times??
Turbulent economic times create new opportunities and threats for CI and BI professionals. This presentation will share field research findings regarding traumatic changes under way in the global bio-pharma and medical device sectors – with case examples illuminating how savvy Pharma Leaders and BI pros survive and thrive by aligning organizational intelligence with rapidly changing leadership teams, organizational structures, business units, brands and priorities. |
| 08.30 –09.15 |
PANEL DISCUSSION LIVE ON BLOOMBERG UTV :
Moderator : Mini Menon : Bloomberg UTV
Kewal Handa :MD, Pfizer Ltd
Suresh Kare :CMD, Indoco Remedies Ltd.
Ranjit Shahani, MD, Novartis India Ltd.
Dr Kamal Sharma, MD, Lupin Ltd.
Sanjay Nirupam, Member of Parliament, Govt of India.
Dr Surinder Singh, Drug Controller of India.
Habil F Khorakiwala, Chairman, Wockhardt Ltd.
Dilip Sanghavi, CMD, Sun Pharmaceuticals Ltd.
Dr Shailesh Iyenger, MD, Aventis Pharma Ltd. |
| 09.15 – Onwards |
Cocktails & Dinner |
|
| |
|
PROGRAM AGENDA:
DAY 2 (Saturday 26th April 2010) |
| 09:15-10:15 |
Registration & Networking Breakfast in Exhibition Hall |
| 10:15-11:00 |
Indian Biotechnology at global map
Kiran Mazumdar Shaw, CMD, Biocon Ltd.
|
| 11:00-12:00 |
Mergers,Acqiisitions & Expansions : The new Look of Managed Healthcare services with global penetration
Moderator:
Vishal Bali, CEO, Fortis Hospitals.
Panelists:
Dr Pratap Reddy, Chairman, Appolo Group
Malvinder Singh, Chairma, Fortis Group,
Dr Ramakant Panda, Vice-Chairman, Asian Heart Institute. |
| 12.00 – 12.30 |
Generics Panel Discussion
Ageing populations, growing importance of emerging markets and rapidly rising treatment costs are causing governments and pharmaceutical companies throughout the world to look closely at the sustainability of their healthcare provision and business models. Economically priced generic medicines provide one the means of managing the budget for pharmaceuticals, meet some of the immediate need of emerging markets and provide opportunities for diversification for Big pharma. In the recent years a strong trend is observed for accelerated development and commercialization of generic pharmaceutical products. This would seriously impact the pharmaceutical companies' ability to recoup their costs and reinvest in other research projects. What needs to be done? What can be done? What should be done first? The Competitive intelligence professionals can benefit from this discussion to better understand the new trends related to the use and commercialization of generic products worldwide and get insights how to enhance competitive position of their companies in the global pharmaceuticals marketplace.
Moderator:
Satya Brahma, Editor-In-Chief, Pharma Leaders Magazine & Chairman : Organising Committee, Pharmaceutical Leadership Summit 2010.
Panelists:
Anandh Balasundaram, Managing Director, AstraZeneca Pharma Pvt Ltd
Dr Krishna M Ella, CMD, Bharat Biotech Ltd
Sandeep Sahney , Managing Director – India & South Asia, Genzyme India Pvt Ltd |
| 12.30 –01.00 |
Emergence of Social Devlopment Sector : Corporates need to focus more on CSR? – A Wockhardt Foundation case study
Huzaifa Khorakiwala, CEO, Wockhardt Foundation & Executive Director, Wockhardt Ltd |
| 01.00 – 02.00 |
Lunch – Break |
| 02.00 – 2.30 |
Offshoring/ Outsourcing: Advantage India
Over the last decade outsourcing has become an important strategic issue for pharmaceutical companies; rising pressure to reduce costs and time-to-market has led to outsourcing not only of traditional non-core functions such as manufacturing and clinical trials, but also increasingly of technically demanding areas such as drug discovery and biotech R&D. Pharmaceutical Outsourcing Strategies is a new report which provides a comprehensive and up to date review of contract research and manufacturing, in addition to key strategies for pharmaceutical companies to optimize their relationships with contractors. Emerging trends are evaluated and offshore outsourcing opportunities are analyzed in the rapidly growing markets of Eastern Europe, China and India. Use this report ’s best practice case studies and unique examination of future outsourcing trends -including cutting edge technologies and novel contract alliances to ensure that you implement the optimal strategies for your company ’s needs.
Moderator:
Dr Gopakumar Nair : Chairman, BDH industries Ltd
Panelists:
Dr P.M.Naik, Project Director, Zydus Cadila Ltd
Venket Jasti, CEO, Suven Life Sciences
Daara Patel, Secretary General – IDMA
Anurag Bagaria, Vice – President .Kemwell Pharma Ltd. |
| 02.30 – 03.00 |
Emergence of SEZ zones : Challenges & Opportunities in 2010
Arun Kumar, MD, Strides Acrolabs Ltd
Indian companies were quick to realize opportunities in the global pharmaceutical manufacturing market and have undertaken significant investment in the last decade in creating capacities of global standards to serve highly attractive regulated markets. Investment in creating capacities that meet stringent global quality parameters such as US FDA, UK MHRA, etc is imperative for Indian players to serve high-value regulated markets. However, the decision to either upgrade the existing facility or create a Greenfield facility is dependent on multiple factors such as the target market, capacity required, technology employed and category of products cytotoxic. Many biological products require a separate standalone facility, tax and fiscal incentives in a special economic zone (SEZ) and dedicated pharma zones, etc. A biggie from the pharma industry said that this is the right time for such contract manufacturer outsourcings (CMO) to invest in building new facilities or upgrading existing facilities because production will have to be increased to meet global demand for anti-diabetic, anti-ulcerants and analgesic drugs. Also, CMOs must be abreast of current good manufacturing practices (cGMP), regulatory compliance as well as IPR issues and constantly revisit and upgrade their existing processes, products while planning for future needs. This will ensure that they are able to meet challenges in the marketplace and gain both mind share and shelf space. Geographical diversification in terms of regulated and emerging markets will help Indian pharma companies mitigate their risk exposures. Indian pharma companies that are able to borrow best practices are those that have a consistent and balanced presence across all kinds of markets and therefore, can learn from best minds in the world, in an environment that is conducive to growth and in a way that optimizes business prospects. As such, reaching out to new geographical markets is essential for sustained growth for Indian pharma companies. |
| 03.00 – 03.30 |
Obama's Impact on Healthcare and Pharma Industry. Obama effect: Pharma outsourcing first victim?
With Barack Obama taking over as the President of the United States, outsourcing of activities from the US to the Indian market might get adversely affected, hitting the pharmaceutical sector the most, "President Obama has a conservative stance on outsourcing of services since he wants to create jobs and protect existing ones (in the US). As the Indian pharma industry is sustaining mainly on outsourcing, especially from the US, the future does not appear very smooth.Most of the Indian manufactures and delivers branded as well as generic pharmaceutical formulations to Russia, CIS, south-east Asian countries, the UK and EU.There will be increased competition in the US generics market since the US Food and Drug Administration-approved plants will enable many players to enter into the US market, earlier ruled exclusively by a few big companies."Companies that are cost-effective and good in supplies will survive. With the global economy in a recession, it would make business sense for Indian pharma companies to address the CIS markets."CIS nations are taking aggressive steps to address their healthcare sector. Therefore, Indian pharma companies should be ready to grab the opportunities available in these markets.Though the healthcare system in the CIS countries are in a process of reformation, there are several challenges for the drug manufacturers. The shift towards the generic market has opened the gates for a variety of international companies and the market has become fiercely competitive Pharma companies have experienced a dip in profit margins on account of the global slowdown, attributing it to competition from China and appreciation of the Rupee against the US dollar. Indian companies, however, have proved their manufacturing and research and development capabilities and the CIS nations can benefit enormously by establishing tie-ups with Indian pharma companies.
"Today, the markets have evolved with time. In countries like Russia, consumers are ready to pay a higher cost for quality and there are international competitors who are fighting for a share of these growing markets. The global meltdown could negatively impact Indian pharma exports but "good relationships with the target audience help to sustain longer in the markets.Marketing of pharma products calls for a strong field-force network complimented with a robust supply-chain. A growing product portfolio is the key to beat competition and this will ensure a constant flow of income into the business
.
J.P.N.Singh, Director, Galpha Labs Ltd |
| 03.30 – 04.15 |
Is the Block-buster Molecule outdated??
Dr R.B.Smarta, Managing Direrctor, Interlink Consultancy Pvt Ltd
This panel discussion will bring together leaders in the drug delivery device market with leaders in the drug development market to discuss how alliances can bring sustainable competitive advantage to both groups and the role CI has in the selection of a partner. Panel members will bring their real-world experience to the presentation and explore how CI has supported the development of partnerships from the early stages of recognizing when a partner was needed to the late stages of marketing the end product and system. Attendees will benefit from this unique insight with a better picture of how to assess device and drug company partnerships and how to build similar partnerships within their own entities.
|
| 04:15-04:45 |
100 Prescriptions for 1 Lac : Is the era of ethical marketing over?
Ruth Desouza, Executive Director, Interlink Marketing Consultancy Pvt Ltd.
In what seems to be a case of giving the fox the job of guarding the henhouse, the government has decided to curb the practice of bribing doctors for promoting drugs by allowing pharmaceutical companies to self-regulate rather than have a legislation to tackle the menace. This is despite the fact that more than a quarter of the members of the Organisation of Pharmaceutical Producers of India (OPPI) an association mainly of multinationals which is estimated to account for 70% of the drug market in India are subsidiaries of companies that have been penalised in the US for illegally promoting various drugs through inducements for doctors. Of the 53 pharma members of the OPPI, over 25% have figured in such cases in the US. This is despite the fact that Pharmaceutical Research and Manufacturers of America (PhRMA), which includes many of these penalised companies, already has a voluntary Code on Interactions with Health Professionals which explicitly prohibits members from giving illegal inducements to doctors to get them to prescribe their products. Many of these companies also claim to have their own stringent ethical guidelines applicable globally regarding interactions with health professionals. When stringent laws in the US, unlike India which has no laws to tackle illegal inducements to doctors, could not stop these companies from indulging in kickbacks to doctors, it is anyone's guess how effective self-regulation can be. However, answering a question in the Rajya Sabha on steps taken to curb drug companies bribing doctors, the department of pharmaceuticals said it has asked pharmaceutical company associations to formulate guidelines and mechanisms for their strict enforcement. The government appears satisfied to leave it at that despite being aware that the largest pharmaceutical associations, OPPI and Indian Drug Manufacturers Association (IDMA) already have codes which don't seem to be enforced at all.
|
| 04.45 – 05.15 |
Can we face the Heat of Globalization ?
Ram Prasad Reddy, Chairman, Aurobindo Pharma Ltd
|
| 05.15 – 05.45 |
Will OTC market boom post 2010? – Key Challenges
Dr Anand Burman, Chairman, Dabur India Ltd.
Highly complex business... The sheer complexity of the products and processes in the pharma industry makes it fiendishly difficult to comprehend. Unless you can tell the difference between bulk drugs and formulations, generics and patented drugs, over the counter (OTC) and non-OTC drugs, don’t even think of picking stocks from the vast universe of pharma stocks. ...with intense competition. Few drug companies can afford to make the massive investments in research and development, which are the key to sustained success in this highly competitive industry. Even the larger Indian companies do not have the resources to take a molecule through clinical trials, which is why they have entered into licensing agreements with large global drug companies. Development of new drugs is expensive, and the odds are not encouraging. Only one out of every 1,000 molecules developed makes it through the pre-clinical stages–and barely one out of every five such molecules passes clinical trials. Few companies have the right stuff... Given their low manufacturing costs, Indian companies are ideally positioned to tap the lucrative export market for generics, once the patented drugs that inspired them go off-patent. Till 2005, drugs with sales amounting to around $40 billion are slated to go off-patent. However, few Indian companies have the wherewithal to exploit this opportunity. Before a drug company can export to the US–the world’s biggest market–it has to get its manufacturing facilities certified by the US Food and Drug Administration (USFDA), and obtain drug-specific marketing approvals from that body. The USFDA has stringent certification norms, and a very small percentage of Indian drug companies worldwide are certified by it. ...so choose with caution. Investing in stocks is rather more involved than buying aspirin over the counter, so you need to exercise some discrimination. To help you choose, we have classified the stocks in the sector into three broad categories. The best of these are the cream of India’s pharma sector. Some others, although not as promising, are reasonably strong medium-term bets. And then there are the anonymous me-toos, to be avoided like the plague. |
| 05.45 – 06.15 |
Networking & Refreshments in Exhibition Hall |
| 06.15 – 06.45 |
Retail Pharmacy Market in India :
Suneeta Reddy, Group CFO, Appolo Group.
The number of present pharmacies in the country, estimated over 5 lacks, has to be looked from a practical positive angle. They too have a role to play - to make the medicines available to the common man at affordable cost.They have survived amidst odds and unhealthy competition due to irrational grant of too many sales licences, unmindful of the need. The industry is growing at 41% per annum and expected to reach INR 432 bn by 2011. Growth in this sector is being propelled by increase in healthcare spending, growth in pharma sector & organized pharma retail, changing disease profile of India, consumer attitudes, attractive margins and growth in OTC segment.The drivers and challenges explain the factors influencing growth of the industry and a brief analysis of the major issues/challenges hindering growth. The report also highlights the current market trends. The competitive landscape profiles the major players in this sector including the business description, number of stores and expansion plans for each player. The report also provides details of the key developments in this sector.The Indian retail industry is the fifth largest in the world. Comprising of organized and unorganized sectors, India retail industry is one of the fastest growing industries in India, especially over the last few years. Though initially, the retail industry in India was mostly unorganized, however with the change of tastes and preferences of the consumers, the industry is getting more popular these days and getting organized as well. With growing market demand, the industry is expected to grow at a pace of 25-30% annually. The India retail industry is expected to grow from Rs. 35,000 crore in 2004-05 to Rs. 109,000 crore by the year 2010.
|
| 06.45 – 07.15 |
How Pharma Leaders Can Survive and Thrive In Turbulent Times??
Turbulent economic times create new opportunities and threats for CI and BI professionals. This presentation will share field research findings regarding traumatic changes under way in the global bio-pharma and medical device sectors – with case examples illuminating how savvy Pharma Leaders and BI pros survive and thrive by aligning organizational intelligence with rapidly changing leadership teams, organizational structures, business units, brands and priorities.
Shailesh Iyenger, MD, Aventis Pharma Ltd.
|
| 07.15 – 07.45. |
Modern Day Practioners : Aims & Aspirations
Dr Ramakant Panda, Vice-Chairman, Asian Heart Institute.
|
| 07:45-08:45. |
Vote of Thanks : satya Brahma, Editor-In-Chief, Pharma Leaders. Pharma Leaders Excellence Awards |
| 8.45 onwards Cocktail & Dinner with a grand Gala evening Surprise |
|
| Top |
|
|
|
